Kura Oncology, Inc. (NASDAQ:KURA) Sees Significant Increase in Short Interest

Kura Oncology, Inc. (NASDAQ:KURA) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 10,440,000 shares, an increase of 17.4% from the December 15th total of 8,890,000 shares. Based on an average trading volume of 1,660,000 shares, the short-interest ratio is presently 6.3 days. Approximately 16.0% of the shares of the stock are short sold.

Analysts Set New Price Targets

KURA has been the subject of a number of research analyst reports. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and dropped their price target for the company from $26.00 to $19.00 in a research report on Monday, October 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research note on Monday, December 9th. Wedbush reissued an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a report on Monday, November 4th. Jefferies Financial Group dropped their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a report on Thursday, November 21st. Finally, HC Wainwright increased their target price on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $27.38.

Hedge Funds Weigh In On Kura Oncology

Several large investors have recently modified their holdings of the stock. nVerses Capital LLC purchased a new position in Kura Oncology in the 3rd quarter worth approximately $25,000. Point72 DIFC Ltd bought a new stake in shares of Kura Oncology in the 3rd quarter worth $146,000. Quarry LP purchased a new position in shares of Kura Oncology in the second quarter worth $196,000. Erste Asset Management GmbH bought a new position in shares of Kura Oncology during the third quarter valued at $215,000. Finally, Bellevue Group AG boosted its position in shares of Kura Oncology by 36.0% during the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after buying an additional 3,600 shares during the last quarter.

Kura Oncology Trading Up 1.1 %

KURA opened at $7.26 on Friday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 52 week low of $6.98 and a 52 week high of $24.17. The stock has a market cap of $564.54 million, a PE ratio of -3.08 and a beta of 0.81. The business has a 50 day moving average of $10.51 and a 200-day moving average of $16.36.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.